Alternative links to fulltext:
| Item type: | Article | ||||
|---|---|---|---|---|---|
| Journal or Publication Title: | Cancer Letters (Shannon, Ireland) | ||||
| Volume: | 131 | ||||
| Number of Issue or Book Chapter: | 1 | ||||
| Page Range: | pp. 101-108 | ||||
| Date: | 1998 | ||||
| Additional Information (public): | CAN 130:104864 1-6 Pharmacology 37326-33-3 (Hyaluronidase) Role: BAC (Biological activity or effector, except adverse), BSU (Biological study, unclassified), THU (Therapeutic use), BIOL (Biological study), USES (Uses) (hyaluronidase addnl. to std. chemotherapy improves outcome for children with malignant brain tumors) | ||||
| Institutions: | Chemistry and Pharmacy > Institute of Pharmacy > Pharmaceutical/Medicinal Chemistry II (Prof. Buschauer) | ||||
| Identification Number: |
| ||||
| Keywords: | Antitumor agents (brain hyaluronidase addnl. to std. chemotherapy improves outcome for children with malignant brain tumors); Development (child, hyaluronidase addnl. to std. chemotherapy improves outcome for children with malignant brain tumors); Brain, neoplasms (hyaluronidase addnl. to std. chemotherapy improves outcome for children with malignant brain tumors); Brain, neoplasms (inhibitors, hyaluronidase addnl. to std. chemotherapy improves outcome for children with malignant brain tumors); child brain tumor chemotherapy hyaluronidase combination | ||||
| Dewey Decimal Classification: | 500 Science > 500 Natural sciences & mathematics 600 Technology > 610 Medical sciences Medicine | ||||
| Status: | Published | ||||
| Refereed: | Yes, this version has been refereed | ||||
| Created at the University of Regensburg: | Partially | ||||
| Item ID: | 5484 |
Abstract
Ex vivo expts. with vital brain tumor samples show that hyaluronidase enhances the permeation of carboplatin into tumor tissue with a matrix rich in hyaluronic acid. We achieved long-lasting second remissions for children with relapsed malignant brain tumors treated with carboplatin, etoposide and this enzyme. Thereafter, we initiated a pilot study where we added hyaluronidase to the first line ...
Abstract
Ex vivo expts. with vital brain tumor samples show that hyaluronidase enhances the permeation of carboplatin into tumor tissue with a matrix rich in hyaluronic acid. We achieved long-lasting second remissions for children with relapsed malignant brain tumors treated with carboplatin, etoposide and this enzyme. Thereafter, we initiated a pilot study where we added hyaluronidase to the first line std. therapy to prevent the deadly relapses right from the beginning. All 19 patients with malignant brain tumors admitted to our pediatric neurooncol. center from 1992 to 1994 were included in the study. Kaplan-Meier estn. of event-free survival and overall survival after 3 yr follow-up indicates a significantly better outcome for the hyaluronidase-treated group. The children receiving supportive hyaluronidase suffered significantly less relapses (P=0.034) and had a significantly better chance for survival (P=0.045) compared to the historical control of 21 children treated with the same std. regimen but without supportive hyaluronidase (product limit anal. and the log-rank test, P<0.05). Children aged >3 yr receiving hyaluronidase together with primary treatment seemed to gain the most benefit.
Metadata last modified: 24 May 2018 10:11
Owner only: item control page
Altmetric